Strides Pharma Science is currently trading at Rs. 433.80, up by 4.95 points or 1.15% from its previous closing of Rs. 428.85 on the BSE.
The scrip opened at Rs. 433.90 and has touched a high and low of Rs. 434.60 and Rs. 429.95 respectively. So far 6950 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 875.72 on 27-Dec-2017 and a 52 week low of Rs. 334.10 on 08-Jun-2018.
Last one week high and low of the scrip stood at Rs. 437.95 and Rs. 417.30 respectively. The current market cap of the company is Rs. 3840.31 crore.
The promoters holding in the company stood at 30.79%, while Institutions and Non-Institutions held 47.54% and 21.68% respectively.
Strides Pharma Science’s step-down wholly owned subsidiary -- Strides Pharma Global Pte, Singapore has entered into an exclusive product development, licensing and supply agreement with SUDA Pharmaceuticals for its novel drug SUD-001H, an oral spray of sumatriptan to treat migraine headache for the US market.
Execution of Strides’ generic product pipeline for the US is nearing completion and is expected to have 150 plus ANDA filings by 2021. The company is now focusing on developing a portfolio of complex and specialty products including products filed under the 505B (2) regulatory pathway.
Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.
